Abstract
Inhibitors of varying potency have been developed for types I and II 3-dehydroquinate dehydratase (dehydroquinase), enzymes from the shikimate and quinate pathways that catalyse the dehydration of dehydroquinate to dehydroshikimate. These inhibitors have resulted from enzyme mechanistic studies and from the direct search for enzyme inhibitors with herbicidal, fungicidal or antimicrobial potential. This review discusses the design of the various inhibitors that have been produced so far and some structure-activity relationships. The majority of these inhibitors are based on dehydroquinate analogues, although some work has also been carried out on dehydroshikimate and bissulfonamides. Some discussion is also presented on advances in the synthesis of these types of compounds.
Keywords: Types I and II Dehydroquinase, dehydroquinate, antimicrobial, herbicidal
Mini-Reviews in Medicinal Chemistry
Title: Inhibitors of Types I and II Dehydroquinase
Volume: 4 Issue: 7
Author(s): Christine Le Sann, Mary A. Gower and Andrew D. Abell
Affiliation:
Keywords: Types I and II Dehydroquinase, dehydroquinate, antimicrobial, herbicidal
Abstract: Inhibitors of varying potency have been developed for types I and II 3-dehydroquinate dehydratase (dehydroquinase), enzymes from the shikimate and quinate pathways that catalyse the dehydration of dehydroquinate to dehydroshikimate. These inhibitors have resulted from enzyme mechanistic studies and from the direct search for enzyme inhibitors with herbicidal, fungicidal or antimicrobial potential. This review discusses the design of the various inhibitors that have been produced so far and some structure-activity relationships. The majority of these inhibitors are based on dehydroquinate analogues, although some work has also been carried out on dehydroshikimate and bissulfonamides. Some discussion is also presented on advances in the synthesis of these types of compounds.
Export Options
About this article
Cite this article as:
Sann Le Christine, Gower A. Mary and Abell D. Andrew, Inhibitors of Types I and II Dehydroquinase, Mini-Reviews in Medicinal Chemistry 2004; 4 (7) . https://dx.doi.org/10.2174/1389557043403567
DOI https://dx.doi.org/10.2174/1389557043403567 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety of Using Copper Oxide in Medical Devices and Consumer Products
Current Chemical Biology 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Infectious Disorders - Drug Targets Expression of Toll-like Receptor 2 and Toll-like Receptor 4 in Tuberculous Pleural Effusion
Medicinal Chemistry Depsipeptides from Microorganisms: A New Class of Antimalarials
Mini-Reviews in Medicinal Chemistry A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry Updated Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from the South American Working Group (Consensur II)
Current Respiratory Medicine Reviews Abiotic Regulation: A Common Way for Proteins to Modulate their Functions
Current Protein & Peptide Science Pharmacogenomics of Arylamine N-acetyltransferase
Current Pharmacogenomics Phosphoserine Aminotransferase has Conserved Active Site from Microbes to Higher Eukaryotes with Minor Deviations
Protein & Peptide Letters Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets In silico Analysis of Toxins of Staphylococcus aureus for Validating Putative Drug Targets
Infectious Disorders - Drug Targets Lead Molecules for Targeted Urease Inhibition: An Updated Review from 2010 -2018
Current Protein & Peptide Science The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design The Role of Toll-Like Receptors and Type I Interferons in Host Responses to Bacteria
Current Immunology Reviews (Discontinued) Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemical and Bioactive Diversities of the Genus Chaetomium Secondary Metabolites
Mini-Reviews in Medicinal Chemistry AIDS-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (HAART)
Current HIV Research Cell Wall Associated Factors of Mycobacterium tuberculosis as Major Virulence Determinants: Current Perspectives in Drugs Discovery and Design
Current Drug Targets Dietary Interventions in Asthma
Current Pharmaceutical Design